In the model of NASH induced by HFD in rats, the treatment with VSL#3 resulted in a reduction in the expression of markers of lipid peroxidation, TNF-α, inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2), when compared with the control group [84]. Here, PTGS2 is linked to metabolic dysfunction-associated steatohepatitis.